239 related articles for article (PubMed ID: 30033447)
1. A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
Saha A; Harowicz MR; Grimm LJ; Kim CE; Ghate SV; Walsh R; Mazurowski MA
Br J Cancer; 2018 Aug; 119(4):508-516. PubMed ID: 30033447
[TBL] [Abstract][Full Text] [Related]
2. Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms.
Grimm LJ; Zhang J; Mazurowski MA
J Magn Reson Imaging; 2015 Oct; 42(4):902-7. PubMed ID: 25777181
[TBL] [Abstract][Full Text] [Related]
3. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
4. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI.
Chang RF; Chen HH; Chang YC; Huang CS; Chen JH; Lo CM
Magn Reson Imaging; 2016 Jul; 34(6):809-819. PubMed ID: 26968141
[TBL] [Abstract][Full Text] [Related]
5. Is there a correlation between 3T multiparametric MRI and molecular subtypes of breast cancer?
Montemezzi S; Camera L; Giri MG; Pozzetto A; Caliò A; Meliadò G; Caumo F; Cavedon C
Eur J Radiol; 2018 Nov; 108():120-127. PubMed ID: 30396643
[TBL] [Abstract][Full Text] [Related]
6. MRI texture analysis in differentiating luminal A and luminal B breast cancer molecular subtypes - a feasibility study.
Holli-Helenius K; Salminen A; Rinta-Kiikka I; Koskivuo I; Brück N; Boström P; Parkkola R
BMC Med Imaging; 2017 Dec; 17(1):69. PubMed ID: 29284425
[TBL] [Abstract][Full Text] [Related]
7. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
Bae MS; Seo M; Kim KG; Park IA; Moon WK
Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer.
Jin YH; Hua QF; Zheng JJ; Ma XH; Chen TX; Zhang S; Chen B; Dai Q; Zhang XH
Cell Physiol Biochem; 2018; 49(1):271-281. PubMed ID: 30138940
[TBL] [Abstract][Full Text] [Related]
9. Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer.
Jiang S; Hong YJ; Zhang F; Li YK
Sci Rep; 2017 Oct; 7(1):13818. PubMed ID: 29062076
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
12. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.
Incoronato M; Grimaldi AM; Cavaliere C; Inglese M; Mirabelli P; Monti S; Ferbo U; Nicolai E; Soricelli A; Catalano OA; Aiello M; Salvatore M
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1680-1693. PubMed ID: 29696443
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors.
Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L
Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
18. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
19. Radiomic features of Pk-DCE MRI parameters based on the extensive Tofts model in application of breast cancer.
Zhou X; Gao F; Duan S; Zhang L; Liu Y; Zhou J; Bai G; Tao W
Phys Eng Sci Med; 2020 Jun; 43(2):517-524. PubMed ID: 32524436
[TBL] [Abstract][Full Text] [Related]
20. Association Between Imaging Characteristics and Different Molecular Subtypes of Breast Cancer.
Wu M; Ma J
Acad Radiol; 2017 Apr; 24(4):426-434. PubMed ID: 27955963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
